Cargando…
Clinical validation and utility of Percepta GSC for the evaluation of lung cancer
The Percepta Genomic Sequencing Classifier (GSC) was developed to up-classify as well as down-classify the risk of malignancy for lung lesions when bronchoscopy is non-diagnostic. We evaluated the performance of Percepta GSC in risk re-classification of indeterminate lung lesions. This multicenter s...
Autores principales: | Mazzone, Peter, Dotson, Travis, Wahidi, Momen M., Bernstein, Michael, Lee, Hans J., Feller Kopman, David, Yarmus, Lonny, Whitney, Duncan, Stevenson, Christopher, Qu, Jianghan, Johnson, Marla, Walsh, P. Sean, Huang, Jing, Lofaro, Lori R., Bhorade, Sangeeta M., Kennedy, Giulia C., Spira, Avrum, Rivera, M. Patricia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278743/ https://www.ncbi.nlm.nih.gov/pubmed/35830375 http://dx.doi.org/10.1371/journal.pone.0268567 |
Ejemplares similares
-
Percepta Genomic Sequencing Classifier and decision-making in patients with high-risk lung nodules: a decision impact study
por: Sethi, Sonali, et al.
Publicado: (2022) -
Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules
por: Johnson, Marla K., et al.
Publicado: (2021) -
Comparing modalities for risk assessment in patients with pulmonary lesions and nondiagnostic bronchoscopy for suspected lung cancer
por: Yu, Diana H., et al.
Publicado: (2022) -
Improving lung cancer screening: An equitable strategy through a tobacco treatment clinic
por: Galiatsatos, Panagis, et al.
Publicado: (2021) -
TRACHEOSTOMY AND COVID-19 ARDS: ONE ACADEMIC CENTER’S EXPERIENCE
por: Kapp, Chris, et al.
Publicado: (2020)